 Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick Foti, LLC KSF are investigating the proposed sale of Pfenex Inc. NYSE: PFNX to Ligand Pharmaceuticals Incorporated NasdaqGM: LGND. Under the terms of the proposed transaction, shareholders of Pfenex will receive 12.00 in cash, and a one-time contingent value right of 2.00 in the event a predefined regulatory milestone is achieved by December 31, 2021, for each share of Pfenex that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. 